EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Tomoyuki Tatenuma, Hiroshi Miyamoto iD

Drug Design, Development and Therapy · 2023

DOI: 10.2147/dddt.s373546 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Tomoyuki Tatenuma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansReceptors, LHRHGonadotropin-Releasing HormoneAndrogen AntagonistsAndrogensPhenylurea CompoundsPyrimidinones

Stichwörter der Autor:innen

androgen deprivation therapygonadotropin-releasing hormone antagonistprostate cancerrelugolix

Substanzen

Receptors, LHRHGonadotropin-Releasing HormoneAndrogen AntagonistsAndrogensrelugolixPhenylurea CompoundsPyrimidinones

Autor:innen und Institutionen

  • Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
  • Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Department of Urology, University of Rochester Medical Center, Rochester, NY, USA.

ORCID-Profile: Hiroshi Miyamoto

Zitieren

APA

Tatenuma, T., & Miyamoto, H. (2023). Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s373546

Vancouver

Tatenuma T, Miyamoto H. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s373546

BibTeX
@article{Tatenuma2023,
  author = {Tatenuma, Tomoyuki and Miyamoto, Hiroshi},
  title = {Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  doi = {10.2147/dddt.s373546}
}
Kostenlos starten →